Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 1Phase 2 Interventional

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

ClinicalTrials.gov ID: NCT07227298

Public ClinicalTrials.gov record NCT07227298. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 7:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AN INTERVENTIONAL OPEN-LABEL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF PF-08634404 IN COMBINATION WITH DIFFERENT ANTICANCER AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B of the study will look at how well the new medicine PF-08634404 works when used together with another medicine. Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.

Study identification

NCT ID
NCT07227298
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Pfizer
Industry
Enrollment
162 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 29, 2026
Primary completion
Mar 7, 2029
Completion
Aug 22, 2033
Last update posted
Jul 21, 2026

2026 – 2033

United States locations

U.S. sites
36
U.S. states
9
U.S. cities
24
Facility City State ZIP Site status
Highlands Oncology Group, PA Fayetteville Arkansas 72703 Recruiting
Highlands Oncology Group, PA Rogers Arkansas 72758 Recruiting
Highlands Oncology Group, PA Springdale Arkansas 72762 Recruiting
Providence Medical Foundation Fullerton California 92835 Recruiting
Providence St. Jude Medical Center - Virginia K. Crosson Cancer Center and Infusion Center Fullerton California 92835 Recruiting
Providence St. Jude Medical Center Fullerton California 92835 Recruiting
Valkyrie Clinical Trials (Additional Site Pharmacy Storage Suite) Los Angeles California 90067 Recruiting
Valkyrie Clinical Trials Los Angeles California 90067 Recruiting
Mission Community Hospital (Satellite Site) Panorama City California 91402 Recruiting
Rocky Mountain Cancer Centers, LLP Denver Colorado 80218 Recruiting
BRCR Medical Center Inc. Coral Springs Florida 33065 Recruiting
Mid Florida Hematology and Oncology Center Orange City Florida 32763 Recruiting
Orlando Health Ambulatory Care Center Orlando Florida 32806 Recruiting
Orlando Health Cancer Institute Orlando Florida 32806 Recruiting
Orlando Health Orlando Regional Medical Center Orlando Florida 32806 Recruiting
BRCR Global - Tamarac Tamarac Florida 33321 Recruiting
Hackensack University Medical Center Hackensack New Jersey 07601 Recruiting
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 Recruiting
Newman Street Imaging Hackensack New Jersey 07601 Recruiting
John Theurer Cancer Center at JSUMC Neptune City New Jersey 07753 Recruiting
John Theurer Cancer Center at From Road Paramus New Jersey 07652 Recruiting
Heart Center Glenpointe Teaneck New Jersey 07666 Recruiting
Montefiore Medical Center- Montefiore Medical Park The Bronx New York 10461 Recruiting
Oncology Associates of Oregon, P.C. Eugene Oregon 97401 Recruiting
Dallas Cancer Specialists Garland Texas 75042 Recruiting
Southwest Oncology Associates Houston Texas 77030 Recruiting
Lumi Research Houston Texas 77090 Recruiting
US Oncology Investigational Products Center (IPC) Irving Texas 75063 Recruiting
Voyage Clinical Sugar Land Texas 77479 Recruiting
VCU Medical Center Gateway Building Richmond Virginia 23219 Recruiting
Virginia Commonwealth University Richmond Virginia 23219 Recruiting
VCU Health Stony Point Richmond Virginia 23235 Recruiting
Massey Cancer Center Clinical & Translational Research Lab Richmond Virginia 23298 Recruiting
Virginia Commonwealth University Richmond Virginia 23298 Recruiting
VCU Health Community Memorial Hospital South Hill Virginia 23970 Recruiting
VCU Health Tappahannock Hospital Tappahannock Virginia 22560 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07227298, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 21, 2026 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07227298 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →